INVO Fertility Stock Scheduled to Reverse Split on Friday, October 30th (NASDAQ:IVF)

INVO Fertility, Inc (NASDAQ:IVF) shares are going to reverse split on Friday, October 30th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, October 29th.

INVO Fertility Stock Up 1.1%

Shares of NASDAQ:IVF traded up $0.01 on Thursday, reaching $0.56. The company had a trading volume of 42,546 shares, compared to its average volume of 1,808,523. INVO Fertility has a 52-week low of $0.51 and a 52-week high of $26.58. The firm’s 50 day simple moving average is $0.86 and its 200-day simple moving average is $2.35. The firm has a market capitalization of $1.41 million, a PE ratio of -0.02 and a beta of 2.39. The company has a current ratio of 0.71, a quick ratio of 0.67 and a debt-to-equity ratio of 0.03.

INVO Fertility (NASDAQ:IVF) last announced its earnings results on Friday, August 14th. The company reported $0.35 earnings per share for the quarter. The firm had revenue of $2.18 million for the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on IVF shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of INVO Fertility in a research note on Monday, August 3rd. Wall Street Zen raised INVO Fertility to a “hold” rating in a report on Saturday, August 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

About INVO Fertility

INVO Fertility, Inc is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment.

Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.

In addition to commercializing INVOcell, INVO Fertility operates and supports fertility centers that provide reproductive services, including IVF and related treatments.